Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa

Meropenem-vaborbactam (MEV) is a novel carbapenem–beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults. In this study, we evaluated the performance of Etest M...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Microbiol
Главные авторы: Jean, Sophonie, Garrett, Sheri, Anglade, Claire, Bridon, Laurence, Davies, Leanne, Garner, Omai B., Richards, Jennifer, Wallace, Meghan, Wootton, Mandy, Burnham, Carey-Ann D.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2019
Предметы:
Bacteriology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935911/
https://ncbi.nlm.nih.gov/pubmed/31619532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.01205-19
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы